AstraZeneca ((AZN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: AstraZeneca is conducting a Phase 1, open-label PET trial titled ‘A Phase 1, Open-label Positron Emission Tomography Trial to Assess Changes in Liver Uptake of [68Ga]Ga-FAPI-46 Following Oral Administration of Single Doses of AZD2389 to Patients With Advanced Liver Fibrosis (PECHORA).’ The study aims to investigate the effect of AZD2389 on FAP occupancy in the liver of participants with advanced liver fibrosis, a condition with significant health implications.
Intervention/Treatment: The study tests AZD2389, an oral drug, alongside a diagnostic PET scan using the radioligand [68Ga]Ga-FAPI-46. The goal is to assess the drug’s impact on liver fibrosis by measuring FAP occupancy.
Study Design: This interventional study is non-randomized and follows a sequential model, meaning participants receive treatments based on prior results. It’s an open-label trial, so both researchers and participants know the treatment being administered. The primary purpose is treatment-focused.
Study Timeline: The study began on May 9, 2025, with the latest update on August 28, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.
Market Implications: This study’s progress could influence AstraZeneca’s stock performance by showcasing its commitment to innovative treatments for liver fibrosis. Positive results may boost investor confidence, while also impacting competitors in the liver fibrosis treatment space.
The study is ongoing, with further details available on the ClinicalTrials portal.